Therapeutic approaches to protein-misfolding diseases

Nature

Volumn 426, Issue 6968, 2003, Pages 905-909

  Cohen, Fred E ^a   Kelly, Jeffery W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; DISEASE CONTROL; DRUG THERAPY; GENETIC ENGINEERING; MOLECULAR BIOLOGY; PATHOLOGY;

CELLULAR PATHOGENESIS; GENETIC DISEASES;

PROTEINS;

BETA SECRETASE INHIBITOR; BORTEZOMIB; CHAPERONE; LIXIVAPTAN; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

DISEASE; PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; CYSTIC FIBROSIS; DISEASE COURSE; ENZYME REPLACEMENT; LYSOSOME STORAGE DISEASE; MOLECULAR MECHANICS; MULTIPLE MYELOMA; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN FOLDING; PROTEIN STABILITY; REVIEW; STEM CELL TRANSPLANTATION; THERMODYNAMICS; TREATMENT OUTCOME;

ALZHEIMER DISEASE; ANIMALS; HUMANS; MOLECULAR CHAPERONES; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEINS; THERMODYNAMICS;

ANIMALIA;

EID: 0346727128     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature02265     Document Type: Review

References (49)

1. Anfinsen, C. B. Principles that govern the folding of protein chains. Science 181, 223-230 (1973).
2. Powell, K. & Zeitlin, P. L. Therapeutic approaches to repair defects in ΔF508 CFTR folding and cellular targeting. Adv. Drug Deliv. Rev. 54, 1395-1408 (2002).
3. Howard, M. & Welch, W. J. Manipulating the folding pathway of ΔF508 CFTR using chemical chaperones. Methods Mol. Med. 70, 267-275 (2002).
4. Carrell R. W. & Lomas D. A. Mechanisms of disease. Alpha 1-antitrypsin deficiency - a model for conformational diseases. N. Engl. J. Med. 346, 45-53 (2002).
5. Rochet, J.-C. & Lansbury, P. T. Jr. Amyloid fibrillogenesis: themes and variations. Curr. Opin. Struct. Biol. 10, 60-68 (2000).
6. Kelly, J. W. Alternative conformations of amyloidogenic proteins govern their behavior. Curr. Opin. Struct. Biol. 6, 11-17 (1996).
7. Fan, J.-Q. A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends Pharm. Sci. 24, 355-360 (2003).
8. Sawkar A. R. et al. Chemical chaperones increase the cellular activity of N370S β-glucosidase: a therapeutic strategy for Gaucher disease. Proc. Natl Acad. Sci. USA 99, 15428-15433 (2002).
9. Morello, J.-P. et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J. Clin. Inv. 105, 887-895 (2000).
10. Petaja-Repo, U. E. et al. Ligands act as pharmacological chaperones and increase the efficiency of δ opioid receptor maturation. EMBO J. 21, 1628-1637 (2002).
11. Janovick, J. A. et al. Structure-activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor. J. Pharm. Exp. Ther. 305, 608-614 (2003).
12. Noorwez, S. M. et al. Pharmacological chaperone-mediated in vivo folding and stabilization of the P23H-opsin mutant associated with autosomal dominant retinitis pigmentosa. J. Biol. Chem. 278, 14442-14450 (2003).
13. Ficker, E., Obejero-Paz, C. A., Zhao, S. & Brown, A. M. The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations J. Biol. Chem. 277, 4989-4998 (2002).
14. Fan, J.-Q., Ishii, S., Asano, N. & Suzuki, Y. Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nature Med. 5, 112-115 (1999).
15. Frustaci, A. et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N. Engl. J. Med. 345, 25-32 (2001).
16. Springsteel, M. F. et al. Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. Bioorg. Medic. Chem. 11, 4113-4120 (2003).
17. Burrows, J. A. J., Willis, L. K. & Perlmutter, D. H. Chemical chaperones mediate increased secretion of mutant α1 -antitrypsin (α1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in α1-AT deficiency. Proc. Natl Acad. Sci. USA 97, 1796-1801 (2000).
18. Hammarstrom, P., Jiang, X., Hurshman, A. R., Powers, E. T. & Kelly, J. W. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc. Natl Acad. Sci. USA 99, 16427-16432 (2002).
19. Hammarstrom, P., Wiseman, R. L., Powers, E. T. & Kelly, J. W. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 299, 713-716 (2003).
20. Schneider, F., Hammarstrom, P. & Kelly, J. W. Transthyretin slowly exchanges subunits under physiological conditions: a convenient chromatographic method to study subunit exchange in oligomeric proteins. Protein Sci. 10, 1606-1613 (2001).
21. Nikolova, P. V., Wong, K.-B., DeDecker, B., Henckel, J. & Fersht, A. R. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J. 19, 370-378 (2000).
22. Sacchettini, J. C. & Kelly, J. W. Therapeutic strategies for human amyloid diseases. Nature Rev. Drug Discov. 1, 267-275 (2002).
23. White, J. T. & Kelly, J. W. Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro. Proc. Natl Acad. Sci. USA 98, 13019-13024 (2001).
24. Korth, C., May, B. C. H., Cohen, F. E. & Prusiner, S. B. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl Acad. Sci. USA 98, 9836-9841 (2001).
25. May, B. C. H. et al. Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Proc. Natl Acad. Sci. USA 100, 3416-3421 (2003).
26. Vogtherr, M. et al. Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein. J. Med. Chem. 46, 3563-3564 (2003).
27. Peretz, D. et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412, 739-743 (2001).
28. White, A. R. et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422, 80-83 (2003).
29. Heppner, F. L. et al. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294, 178-182 (2001).
30. Solomon, B. Anti-aggregating antibodies, a new approach towards treatment of conformational diseases. Curr. Med. Chem. 9, 1737-1749 (2002).
31. Telling, G. C. et al. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 83, 79-90 (1995).
32. Ohno, S. et al. The antisense approach in amyloid light chain amyloidosis: identification of monoclonal 1g and inhibition of its production by antisense oligonucleotides in in vitro and in vivo models. J. Immunol. 169, 4039-4045 (2002).
33. Findeis, M. A. Peptide inhibitors of beta amyloid aggregation. Curr. Top. Med. Chem. 2, 417-423 (2002).
34. Yang, D.-S. et al. Assembly of Alzheimer's amyloid-β fibrils and approaches for therapeutic intervention. Amyloid 8, 10-19 (2001).
35. Howlett, D. R. et al. Inhibition of fibril formation in β-amyloid peptide by a novel series of benzofurans. Biochem. J. 340, 283-289 (1999).
36. Kelly, J. W. & Balch, W. E. Amyloid as a natural product. J. Cell Biol. 161, 461-462 (2003).
37. Lamber, M. P. et al. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA 95, 6448-6453 (1998).
38. Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489 (2003).
39. Walsh, D. M. et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-339 (2002).
40. Wolfe, M. S. γ-Secretase as a target for Alzheimer's disease. Curr. Top. Med. Chem. 2, 371-383 (2002).
41. Vassar, R. β-Secretase (BACE) as a drug target for Alzheimer's disease. Adv. Drug Deliv. Rev. 54, 1589-1602 (2002).
42. Jarrett, J. T. & Lansbury, P. T. Jr. Seeding 'one-dimensional crystallization' of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73, 1055-1058 (1993).
43. Golde, T. E., Eriksen, J. L., Weggen, S., Sagi, S. A. & Koo, E. H. Nonsteroidal antiinflammatory drugs as therapeutic agents for Alzheimer's disease. Drug Dev. Res. 56, 415-420 (2002).
44. Spooner, E. T., Desai, R. V., Mori, C., Leverone, J. F. & Lemere, C. A. The generation and characterization of potentially therapeutic Aβ antibodies in mice: differences according to strain and immunization protocol. Vaccine 21, 290-297 (2002).
45. Nicoll, J. A. R. et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nature Med. 9, 448-452 (2003).
46. Solomon, B. Protective molecules in Alzheimer's disease: therapeutic antibodies. Drug News Perspect. 15, 410-416 (2002).
47. Colon, W. & Kelly, J. W. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31, 8654-8660 (1992).
48. Fandrich, M., Fletcher, M. A. & Dobson, C. M. Amyloid fibrils from muscle myoglobin. Nature 410, 165-166 (2001).
49. Baskakov, I. V., Legname, G., Prusiner, S. B. & Cohen, F. E. Folding of prion protein to its native α-helical conformation is under kinetic control. J. Biol. Chem. 276, 19687-19690 (2001).